Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Common Equity (2016 - 2025)

Historic Common Equity for AtriCure (ATRC) over the last 17 years, with Q3 2025 value amounting to $476.5 million.

  • AtriCure's Common Equity rose 247.0% to $476.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $476.5 million, marking a year-over-year increase of 247.0%. This contributed to the annual value of $461.0 million for FY2024, which is 111.53% down from last year.
  • According to the latest figures from Q3 2025, AtriCure's Common Equity is $476.5 million, which was up 247.0% from $464.5 million recorded in Q2 2025.
  • In the past 5 years, AtriCure's Common Equity ranged from a high of $488.5 million in Q3 2021 and a low of $385.1 million during Q2 2021
  • In the last 5 years, AtriCure's Common Equity had a median value of $462.1 million in 2024 and averaged $455.9 million.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 7207.63% in 2021, then tumbled by 781.24% in 2022.
  • AtriCure's Common Equity (Quarter) stood at $483.8 million in 2021, then fell by 5.58% to $456.8 million in 2022, then rose by 2.06% to $466.2 million in 2023, then fell by 1.12% to $461.0 million in 2024, then rose by 3.37% to $476.5 million in 2025.
  • Its Common Equity was $476.5 million in Q3 2025, compared to $464.5 million in Q2 2025 and $454.6 million in Q1 2025.